IV 

118TH CONGRESS 

2D SESSION H. RES. 1580 

Supporting the designation of July as Uterine Fibroids Awareness Month. 

IN THE HOUSE OF REPRESENTATIVES 

NOVEMBER 18, 2024 

Mr. DAVID SCOTT of Georgia (for himself, Ms. CLARKE of New York, Ms. 

WILLIAMS of Georgia, Mr. MULLIN, Mrs. WATSON COLEMAN, and Ms. 

PRESSLEY) submitted the following resolution; which was referred to the 

Committee on Energy and Commerce 

RESOLUTION 

Supporting the designation of July as Uterine Fibroids 

Awareness Month. 

Whereas fibroids may cause significant morbidity through 

their presence in the uterus and pelvic cavity, causing 

significant pelvic pain, abnormal uterine bleeding, reproductive dysfunction, miscarriages, and even infertility; 

Whereas the pain, discomfort, stress, and other physical and 

emotional symptoms of living with fibroids may significantly interfere with a woman’s quality of life, compromising her ability to function normally, work, or care for 

her family, and may lead to more severe health and 

wellness issues; 

Whereas uterine fibroids are the most prevalent medical condition affecting women, with an estimated 30 percent of 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HRES 1580 IH 

women developing a uterine fibroid by age 35, and 80 

percent of women developing a uterine fibroid by age 50; 

Whereas the exact number of affected women is unknown, as 

early detection and diagnosis are difficult because only 1 

out of 4 women who have a uterine fibroid exhibit symptoms severe enough to require treatment; 

Whereas the overall incidence of uterine fibroids is estimated 

to disproportionately impact Black and Hispanic women, 

who also experience more severe symptoms, resulting in 

an incidence rate that is 3 times greater in women with 

Black ancestry and 2 times greater in Hispanic women 

compared to Caucasian women; 

Whereas a hysterectomy, or removal of the uterus, is among 

the most common surgical treatments for uterine 

fibroids, and more than 200,000 hysterectomies are performed each year to treat uterine fibroids, at an estimated annual cost of more than $2,000,000,000; 

Whereas uterine fibroids were estimated to cost the United 

States $5,900,000,000 to $34,400,000,000 annually with 

an estimated annual lost work cost of $1,600,000,000 to 

$17,200,000,000 through absenteeism and short-term 

disability in women ages 25 to 54; and 

Whereas public awareness and education campaigns on uterine fibroids prevention, screening, and symptoms are held 

during the month of July each year: Now, therefore, be 

it 

1 Resolved, That the House of Representatives— 

2 (1) supports the goals and ideals of Uterine 

3 Fibroids Awareness Month; 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HRES 1580 IH 

1 (2) recognizes the disparity in incidence rates 

2 for Black and Hispanic uterine fibroid patients; 

3 (3) recognizes the need for greater research, 

4 treatment, and care options regarding uterine 

5 leiomyoma; and 

6 (4) encourages the President to issue a procla7 mation calling upon the people of the United States 

8 to observe the month with appropriate awareness 

9 and educational activities. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS